This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IDEXX (IDXX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) Q2 performance will likely benefit from strong sales from the CAG Diagnostics and Water businesses.
Brainsway Ltd. Sponsored ADR (BWAY) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Brainsway Ltd. Sponsored ADR (BWAY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Edwards Lifesciences (EW) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Edwards Lifesciences' (EW) Q2 performance will likely reflect the continued adoption of the RESILIA tissue valves and enhanced sales of the HemoSphere platform.
Exact Sciences (EXAS) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Exact Sciences' (EXAS) Q2 performance will likely reflect the benefit from continued adoption of the Oncotype DX breast test and robust Cologuard screening revenues.
Charles River (CRL) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.
STERIS (STE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) Key Surgical and Cantel Medical businesses make significant contributions to consumable revenues within the Healthcare arm in Q1.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Bio-Rad's (BIO) Clinical Diagnostics segment is expected to report growth in Q2, driven by its focus on laboratory workflow productivity, quality control, and new opportunities in molecular diagnostics.
Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) S.E.T. arm is expected to deliver strong results on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.
Lantheus (LNTH) to Report Q2 Results: What's in the Cards?
by Zacks Equity Research
Lantheus' (LNTH) Q2 performance is likely to gain from the continued uptake of PYLARIFY and DEFINITY.
Quest Diagnostics (DGX) Tops Q2 Earnings Estimates, Ups View
by Zacks Equity Research
Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raises its full-year 2022 guidance.
Abbott's (ABT) Q2 Earnings Top Estimates, '22 EPS View Up
by Zacks Equity Research
Abbott (ABT) reports better-than-expected results for Q2 2022, with robust contributions from the Established Pharmaceuticals, Diagnostics and Medical Device segments.
LabCorp (LH) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
LabCorp's (LH) Diagnostics base business organic volume is anticipated to have continued its rally in Q2, led by consistent growth in esoteric and routine procedures.
Molecular Diagnostics Sales to Drive Hologic (HOLX) Q3 Earnings
by Zacks Equity Research
Hologic's (HOLX) Q3 performance will likely benefit from the increased utilization of Panther instruments and contributions from its recent acquisitions.
What's in Store for Thermo Fisher (TMO) in Q2 Earnings?
by Zacks Equity Research
The emergence of the new virus variants, through the months of Q2, is likely to have led to top-line contributions within Thermo Fisher's (TMO) Life-Science Solutions segment.
What's in Store for Boston Scientific (BSX) in Q2 Earnings?
by Zacks Equity Research
Within the PI business of Boston Scientific (BSX), Q2 sales are expected to have been strong, banking on the strong performance of the drug-eluting franchise.
Wall Street Analysts Believe Brainsway Ltd. Sponsored ADR (BWAY) Could Rally 159%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 158.6% in Brainsway Ltd. Sponsored ADR (BWAY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Brainsway Ltd. Sponsored ADR (BWAY) Stock Jumps 9.4%: Will It Continue to Soar?
by Zacks Equity Research
Brainsway Ltd. Sponsored ADR (BWAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
BrainsWay (BWAY) is in Overbought Territory: What's Next?
by Zacks Equity Research
BrainsWay (BWAY) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Brainsway Ltd. Sponsored ADR (BWAY) Moves 10.6% Higher: Will This Strength Last?
by Zacks Equity Research
Brainsway Ltd. Sponsored ADR (BWAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Should You Buy BrainsWay (BWAY) Ahead of Earnings?
by Zacks Equity Research
BrainsWay (BWAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
STERIS (STE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS (STE) is likely to have continued to gain from the robust demand of PPE and COVID-19-related products in Q4.
Strength Seen in Brainsway Ltd. Sponsored ADR (BWAY): Can Its 7.3% Jump Turn into More Strength?
by Zacks Equity Research
Brainsway Ltd. Sponsored ADR (BWAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) witnessed revenue growth across two business segments in fiscal Q1.
NEOGEN (NEOG) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
NEOGEN's (NEOG) segmental revenues improve for the fiscal first quarter on strong sales of cleaners, disinfectants and sanitizers.
Brainsway's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Brainsway.